archive-org.com » ORG » M » MATWIN.ORG

Total: 320

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Industrial Partner : Bristol-Myers Squibb
    2016 the 2nd edition of Read more Subscribe to Coming next AGENDA Cancéropôle PACA annual congress June 30th July 1st 2016 The Cancéropôle PACA is organizing on June 30th and July 1st 2016 Read more Subscribe to Industrial partners Back to list Bristol Myers Squibb As a global BioPharma leader Bristol Myers Squibb uniquely combines the reach and resources of a major pharmaceutical company with the can do spirit and agility of an innovative biotech The guiding principles and values behind our business strategy are expressed in the company s Mission to discover develop and deliver innovative medicines that help patients prevail over serious diseases Over the years Bristol Myers Squibb and its employees have received numerous distinguished awards and recognitions including the National Medal of Technology the Lasker Award for Medical Research and the Prix Galien Award Their success as a BioPharma leader has been fueled by their pioneering approach to bolster their early and mid stage research and pipeline through a series of acquisitions collaborations alliances and agreements They have helped balance their portfolio and build clusters of expertise in key therapeutic areas where there is great unmet medical need And they ve positioned themselves as a strong

    Original URL path: http://www.matwin.org/actors_involved/industrial_partners_bristol_myers_squibb-f25.html (2016-02-11)
    Open archived version from archive


  • Celgene - MATWIN industrial partner
    Read more Subscribe to Coming next AGENDA Cancéropôle PACA annual congress June 30th July 1st 2016 The Cancéropôle PACA is organizing on June 30th and July 1st 2016 Read more Subscribe to Industrial partners Back to list Celgene Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide At Celgene we seek to deliver truly innovative and life changing drugs for our patients Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery the development and the commercialization of products for the treatment of cancer and other severe immune inflammatory conditions There are more than 300 clinical trials at major medical centers using compounds from Celgene Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers including multiple myeloma myelodysplastic syndromes chronic lymphocyte leukemia CLL non Hodgkin s lymphoma NHL myelofibrosis small cell lung cancer and prostate cancer As committed as we are to clinical accomplishment we are equally committed to patient support which is a guiding principle at Celgene We believe all who can benefit from our discoveries should have the opportunity to do so Celgene puts patients first with industry leading programs

    Original URL path: http://www.matwin.org/actors_involved/industrial_partners_celgene-f26.html (2016-02-11)
    Open archived version from archive

  • GSK : MATWIN industrial partner
    edition of Read more Subscribe to Coming next AGENDA Cancéropôle PACA annual congress June 30th July 1st 2016 The Cancéropôle PACA is organizing on June 30th and July 1st 2016 Read more Subscribe to Industrial partners Back to list GlaxoSmithKline GlaxoSmithKline is a science led global healthcare company that researches and develops a broad range of innovative medicines and brands The company has three primary areas of business in pharmaceuticals vaccines and consumer healthcare Their success depends on creating innovative new products and making these accessible to as many people who need them as possible Their headquarters are located in the UK and they have offices in more than 115 countries plus major research centres in the UK USA Spain Belgium and China GSK is one of the few healthcare companies researching medicines and vaccines for the World Health Organisation s three priority diseases HIV AIDS tuberculosis and malaria Their pharmaceuticals business researches develops and makes available medicines that treat a variety of serious and chronic diseases They have medicines available or in development in a wide range of areas including infectious diseases cancer epilepsy heart disease asthma and chronic obstructive pulmonary disease Their vaccine business is one of the

    Original URL path: http://www.matwin.org/actors_involved/industrial_partners_glaxosmithkline-f52.html (2016-02-11)
    Open archived version from archive

  • Janssen: MATWIN industrial partner
    13th 2016 the 2nd edition of Read more Subscribe to Coming next AGENDA Cancéropôle PACA annual congress June 30th July 1st 2016 The Cancéropôle PACA is organizing on June 30th and July 1st 2016 Read more Subscribe to Industrial partners Back to list Janssen Janssen is a Johnson Johnson company which operates in three major fields Pharmacy with human medications as a main specialty in the group activity Consumer healthcare intended for a general public And eventually medical devices and diagnostics Janssen is developing treatments for patients in five important therapeutic areas of healthcare cardiovascular and metabolism diseases immunology infectious diseases and vaccines neuroscience and oncology Janssen has an extensive portfolio of innovative pharmaceutical products in onco hematology lymphomia leukemia chemotherapy induced anemia prostate cancer ovarian cancer Janssen is part of a group owning great therapeutic resources Beyond improving existing therapeutic solutions the challenge for innovation in health issues also includes rare and incurable complex or degenerative diseases of our time Janssen made the conscious choice to rush and foster on innovation The launch of new innovative and highly specialized drugs will be Janssen s challenge and focus for the future Beyond the discovery of innovative medicines Janssen is developing

    Original URL path: http://www.matwin.org/actors_involved/industrial_partners_janssen-f139.html (2016-02-11)
    Open archived version from archive

  • Industrial Partner : Novartis
    address the evolving needs of patients and societies Focused solely on healthcare Novartis offers a diversified portfolio to best meet these needs innovative medicines eye care products cost saving generic pharmaceuticals consumer health products preventive vaccines and diagnostic tools Novartis is the only company with leading positions in each of these areas Novartis is the only company with leading positions in each of these key areas pharmaceuticals innovative patent protected

    Original URL path: http://www.matwin.org/actors_involved/industrial_partners_novartis-f55.html (2016-02-11)
    Open archived version from archive

  • Pfizer
    significantly impact the lives of cancer patients Their research team uses a multi disciplinary approach to identify and target specific alterations that drive the growth and progression of malignant disease They combine innovative approaches to drug discovery with a strong emphasis on precision medicine which matches targeted therapies with the patients most likely to respond to those therapies Their core research and development interests include cancer cell signaling mechanisms and

    Original URL path: http://www.matwin.org/actors_involved/industrial_partners_pfizer-f138.html (2016-02-11)
    Open archived version from archive

  • Industrial Partner : Pierre Fabre
    2nd edition of Read more Subscribe to Coming next AGENDA Cancéropôle PACA annual congress June 30th July 1st 2016 The Cancéropôle PACA is organizing on June 30th and July 1st 2016 Read more Subscribe to Industrial partners Back to list Pierre Fabre Pierre Fabre is the 3rd largest French pharmaceutical group In 2013 its sales reached 2 Billion with international revenues accounting for 56 Founded and its headquarters still based in the South west of France Pierre Fabre currently has branches in 44 countries and distribution agreements in over 130 countries Through the Pierre Fabre Participations holding company the Pierre Fabre Foundation a government recognized public interest foundation owns 86 of Pierre Fabre Laboratories Remaining shares are owned by company employees 7 and through treasury stock 7 Covering all aspects of healthcare from prescription drugs and OTC products to dermo cosmetics Pierre Fabre Laboratories employ over 10 000 people worldwide In 2013 Pierre Fabre allocated more than 17 of its drug revenues to R D focusing on three main areas oncology dermatology and neuropsychiatry Its products and innovative solutions address the full spectrum of health care needs from high prevailing pathologies such as cancer or atopical dermatitis to rare diseases

    Original URL path: http://www.matwin.org/actors_involved/industrial_partners_pierre_fabre-f100.html (2016-02-11)
    Open archived version from archive

  • Industrial Partner : roche
    is organizing on June 30th and July 1st 2016 Read more Subscribe to Industrial partners Back to list Roche Roche s pharmaceutical development is unmatched in the industry Roche has a deep understanding of disease the therapeutic modalities that help bring our research to life and world class translational medicine expertise to drive it through proof of concept and mechanism Roche laboratories have applied world class top level science across the entire value chain to benefit the patient Treatments for breast and gastric cancer hepatitis B and hepatitis C are early successes Roche is also the world s largest in vitro diagnostic provider supports and partners with Roche Pharma at every step along the value chain from discovery to development to market With a strategy of developing innovative targeted medicines Roche is well positioned to meet the future needs of healthcare and has already begun to make Personalised Healthcare a reality In oncology Roche offers tests to identify patients with breast and stomach cancer showing over expression of specific genes and thus will benefit from targeted treatments Roche is also developing a new test to identify a skin cancer causing genetic mutation the target of their new cancer drug candidate

    Original URL path: http://www.matwin.org/actors_involved/industrial_partners_roche-f56.html (2016-02-11)
    Open archived version from archive



  •